- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
- 个人中心
- 退出登录
浏览全部资源
扫码关注微信
- Journal Information
- Journal Introduction
- Editorial Board
- Youth Editorial Board
- Editorial Board Charter
- Subscriptions
- Archive
- Current Issue
- Past Issues
- Priority Publication
- Virtual Collection
- Recommended Articles
- Submission
- Submission Process
- Submission Guidelines
- Download
- Contact us
- For Reviewers
- Guidelines for Reviewers
- Peer Reviewed Policies
- Statement and Policies
- Ethics and Malpractice
- Research Ethics Policies
- Repetition Detection
- Corrections and Retractions
- Editorial Policies
- Open Access Statement
- Website Responsibility
Clinical efficacy of camrelizumab combined with apatinib versus camrelizumab combined with chemotherapy regimens as first-line treatment for advanced gastric cancer
- ZHONGGUO YAOFANG Vol. 36, Issue 18, Pages: 2307-2311(2025)
- 作者机构：
1.安徽医科大学附属滁州医院（滁州市第一人民医院）南区急诊外科，安徽 滁州;239000
2.安徽医科大学附属滁州医院（滁州市第一人民医院）南区急诊科，安徽 滁州 239000
3.安徽医科大学附属滁州医院（滁州市第一人民医院）北区肿瘤内科，安徽 滁州 239000
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2025.18.16
CLC： R969.4;R735.2Received：13 May 2025，
Revised：2025-08-28，
Accepted：29 August 2025，
Published：30 September 2025
- 稿件说明：
移动端阅览
琚然,缪琦,杨军,等.卡瑞利珠单抗联合阿帕替尼与其联合化疗方案一线治疗晚期胃癌的临床效果对比[J].中国药房,2025,36(18):2307-2311.
JU Ran,MIAO Qi,YANG Jun,et al.Clinical efficacy of camrelizumab combined with apatinib versus camrelizumab combined with chemotherapy regimens as first-line treatment for advanced gastric cancer[J].ZHONGGUO YAOFANG,2025,36(18):2307-2311.
琚然,缪琦,杨军,等.卡瑞利珠单抗联合阿帕替尼与其联合化疗方案一线治疗晚期胃癌的临床效果对比[J].中国药房,2025,36(18):2307-2311. DOI： 10.6039/j.issn.1001-0408.2025.18.16.
JU Ran,MIAO Qi,YANG Jun,et al.Clinical efficacy of camrelizumab combined with apatinib versus camrelizumab combined with chemotherapy regimens as first-line treatment for advanced gastric cancer[J].ZHONGGUO YAOFANG,2025,36(18):2307-2311. DOI： 10.6039/j.issn.1001-0408.2025.18.16.
摘要
目的
2
对比卡瑞利珠单抗联合阿帕替尼与卡瑞利珠单抗联合化疗方案一线治疗晚期胃癌的临床疗效及安全性。
方法
2
采用前瞻性随机对照研究设计，将滁州市第一人民医院2022年3月至2024年12月收治的99例晚期胃癌患者按照随机数字表法分组，其中48例采用卡瑞利珠单抗联合化疗方案治疗（对照组），51例采用卡瑞利珠单抗联合阿帕替尼治疗（观察组）。比较两组患者治疗后的临床疗效，治疗前后的血清肿瘤标志物[癌胚抗原（CEA）、糖类抗原（CA）724、CA199和CA242
]
和免疫功能指标（CD3
+
、CD4
+
、CD8
+
及CD4
+
/CD8
+
）水平，以及治疗期间药物不良反应（ADR）发生情况。
结果
2
观察组和对照组分别有2、3例患者脱落。观察组患者的疾病控制率与客观缓解率分别为95.92%、85.71%，分别显著高于对照组的80.00%、55.56%（
P
＜0.05）。观察组患者的中位无进展生存期为9.61个月，显著长于对照组的6.72个月（
P
＝0.011）。治疗前，两组患者的各项血清肿瘤标志物和免疫功能指标水平比较，差异均无统计学意义（
P
＞0.05）；治疗后，两组患者的CEA、CA724、CA199、CA242水平均显著低于治疗前，CD3
+
、CD4
+
水平及CD4
+
/CD8
+
值均显著高于治疗前，且观察组均显著优于对照组（
P
＜0.05）。两组患者ADR总发生率和严重ADR发生率比较，差异均无统计学意义（
P
＞0.05）。
结论
2
卡瑞利珠单抗联合阿帕替尼作为晚期胃癌一线治疗方案在临床疗效和患者免疫功能改善方面较卡瑞利珠单抗联合化疗方案具有一定优势，且总体安全性可接受。
Abstract
OBJECTIVE
2
To compare the clinical efficacy and safety of camrelizumab combined with apatinib versus camrelizumab combined with chemotherapy as first-line treatment for advanced gastric cancer.
METHODS
2
A prospective randomized controlled trial was conducted， enrolling 99 patients with advanced gastric cancer admitted to the Chuzhou First People’s Hospital from March 2022 to December 2024. Patients were randomly assigned using a random number table： 48 received camrelizumab plus chemotherapy （control group）， and 51 received camrelizumab plus apatinib （observation group）. Clinical efficacy， serum tumor marker[carcinoembryonic antigen（CEA），carbohydrate antigen（CA）724，CA199，CA242
]
levels， immune function indicators（CD3
+
，CD4
+
，CD8
+
，CD4
+
/CD8
+
） levels before and a
fter treatment， and adverse drug reaction （ADR） during treatment were compared between the 2 groups.
RESULTS
2
A total of 2 patients in the observation group and 3 in the control group were lost to follow-up. The disease control rate and objective response rate in the observation group were 95.92% and 85.71%， respectively， both significantly higher than 80.00% and 55.56% in the control group （
P
＜0.05）. The median progression-free survival was 9.61 months in the observation group， significantly longer than 6.72 months in the control group （
P
＝0.011）. Before treatment， there was no statistically significant difference in the levels of serum tumor markers and immune function indicators between the 2 groups （
P
＞0.05）. After treatment， the levels of CEA， CA724， CA199 and CA242 in 2 groups were significantly lower than before treatment， while the levels of CD3⁺， CD4⁺ and CD4⁺/CD8⁺ were significantly higher than before treatment， with greater improvements in the observation group （all
P
＜0.05）. The overall incidences of ADR and severe ADR showed no statistically significant difference between the 2 groups （
P
＞0.05）.
CONCLUSIONS
2
Camrelizumab combined with apatinib as first-line therapy for advanced gastric cancer may offer advantages over camrelizumab plus chemotherapy in terms of clinical efficacy and immune function improvement of patients， with an acceptable safety profile.
关键词
Keywords
references
SMYTH E C ， NILSSON M ， GRABSCH H I ， et al . Gastric cancer [J ] . Lancet ， 2020 ， 396 （ 10251 ）： 635 - 648 .
IZUISHI K ， MORI H . Recent strategies for treating stage Ⅳ gastric cancer：roles of palliative gastrectomy，chemotherapy，and radiotherapy [J ] . J Gastrointestin Liver Dis ， 2016 ， 25 （ 1 ）： 87 - 94 .
梁寒 . 局部进展期/Ⅳ期胃或食管胃结合部腺癌新辅助及转化治疗进展 [J ] . 腹部外科 ， 2023 ， 36 （ 2 ）： 79 - 82，87 .
JANJIGIAN Y Y ， SHITARA K ， MOEHLER M ， et al . First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric，gastro-oesophageal junction，and oesophageal adenocarcinoma（CheckMate 649）：a randomised，open-label，phase 3 trial [J ] . Lancet ， 2021 ， 398 （ 10294 ）： 27 - 40 .
QIN S K ， CHAN S L ， GU S Z ， et al . Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma（CARES-310）：a randomised，open-label，international phase 3 study [J ] . Lancet ， 2023 ， 402 （ 10408 ）： 1133 - 1146 .
LI S ， YU W B ， XIE F ， et al . Neoadjuvant therapy with immune checkpoint blockade，antiangiogenesis，and chemotherapy for locally advanced gastric cancer [J ] . Nat Commun ， 2023 ， 14 （ 1 ）： 8 .
黄大伟 ， 江诗怡 ， 厉晶萍 ， 等 . 阿帕替尼联合卡瑞利珠单抗治疗中晚期肝细胞癌的疗效及其对患者免疫功能、肿瘤标志物的影响 [J ] . 中国普通外科杂志 ， 2024 ， 33 （ 7 ）： 1070 - 1077 .
PENG Z ， WEI J ， WANG F ， et al . Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma [J ] . Clin Cancer Res ， 2021 ， 27 （ 11 ）： 3069 - 3078 .
LI C ， ZHENG Y ， SHI Z ， et al . 1512MO perioperative camrelizumab（C） combined with rivoceranib（R） and chemotherapy（chemo） versus chemo for locally advanced resectable gastric or gastroesophageal junction（G/GEJ） adenocarcinoma：the first interim analysis of a randomized，phase Ⅲ trial（DRAGON Ⅳ） [J ] . Ann Oncol ， 2023 ， 34 ： S852 .
SCHWARTZ L H ， LITIÈRE S ， DE VRIES E ， et al . RECIST 1.1-update and clarification：from the RECIST Committee [J ] . Eur J Cancer ， 2016 ， 62 ： 132 - 137 .
MOLLICA V ， RIZZO A ， MARCHETTI A ， et al . The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients：the MOUSEION-06 study [J ] . Clin Exp Med ， 2023 ， 23 （ 8 ）： 5039 - 5049 .
GAO W J ， LIU Y Y ， YUAN C R . International evaluation system for adverse events of chemotherapeutic drugs in cancer treatment：CTCAE v4.0 [J ] . Tumor ， 2012 ， 32 （ 2 ）： 142 - 144 .
LIN J X ， TANG Y H ， ZHENG H L ， et al . Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer：a multicenter randomized phase 2 trial [J ] . Nat Commun ， 2024 ， 15 （ 1 ）： 41 .
XU M L ， MENG X R ， LU Y ， et al . Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer [J ] . J Gastrointest Oncol ， 2022 ， 13 （ 2 ）： 548 - 558 .
CHEN X F ， XU H ， CHEN X B ， et al . First-line camrelizumab （a PD-1 inhibitor） plus apatinib （a VEGFR-2 inhibitor） and chemotherapy for advanced gastric cancer（SPACE）：a phase 1 study [J ] . Signal Transduct Target Ther ， 2024 ， 9 （ 1 ）： 73 .
LEE W S ， YANG H ， CHON H J ， et al . Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity [J ] . Exp Mol Med ， 2020 ， 52 （ 9 ）： 1475 - 1485 .
HACK S P ， ZHU A X ， WANG Y L . Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways：challenges and opportunities [J ] . Front Immunol ， 2020 ， 11 ： 598877 .
CUI Z ， ZHANG J J ， ZHANG J ， et al . Evaluation of IgG，IgM，CD4 + and CD8 + T cells during neoadjuvant chemotherapy with tezio and apatinib in gastric cancer patients [J ] . Cell Mol Biol（Noisy-le-grand） ， 2020 ， 66 （ 3 ）： 113 - 118 .
XIE C F ， ZHOU X ， LIANG C H ， et al . Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer [J ] . J Exp Clin Cancer Res ， 2021 ， 40 （ 1 ）： 266 .
YI M ， ZHENG X L ， NIU M K ， et al . Combination strategies with PD-1/PD-L1 blockade：current advances and future directions [J ] . Mol Cancer ， 2022 ， 21 （ 1 ）： 28 .
YUAN L ， JIA G D ， LV X F ， et al . Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma：a single-arm，phase 2 trial [J ] . Nat Commun ， 2023 ， 14 （ 1 ）： 4893 .
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.